NCT00731679

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 623 (actual)
• Sponsor: Bausch Health Americas, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.

Conditions

• Non-Constipation Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	Rifaximin
DRUG	Placebo

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-08-01
• Completion: 2009-09-01
• First posted: 2008-08-11
• Last updated: 2019-11-29
• Results posted: 2014-07-28

Locations

96 sites across 2 countries: United States, Canada